Keyword: Gilead Sciences

city view

JPM Monday roundup

Well, let’s start with the obvious, a pattern that has been set for a good few years now: There were no M&A deals.

14. Selonsertib

Gilead Sciences’ ASK1 inhibitor selonsertib was viewed as a front-runner in the challenging nonalcoholic steatohepatitis category until it hit a wall this year, missing the mark in a pair of phase 3 trials that spelled the end of the program.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.